Beneficial Effects of Nebivolol in Comparison with Atenolol on Safety and Tolerability in Essential Hypertension

被引：10

作者：

Bhosale, Vivek V. ^{[1
]}

Inamdar, S. C. ^{[2
]}

Karande, V. B. ^{[2
]}

Burute, S. R. ^{[2
]}

Murthy, M. B. ^{[2
]}

Ghatak, A. ^{[1
]}

机构：

[1] CSIR Cent Drug Res Inst, Clin & Expt Med, Commun Number 8682,8510-1 Sect 10, Lucknow 226031, Uttar Pradesh, India

[2] Govt Med Coll, Dept Pharmacol, Miraj, Maharashtra, India

来源：

JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH | 2014年 / 8卷 / 06期

关键词：

Hypertension; Nebivolol; Atenolol;

D O I：

10.7860/JCDR/2014/7728.4419

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction: Hypertension, "The silent killer" is a multifactorial disorder which is asymptomatic and if left untreated leads to lethal complications. Nebivolol is a third generation beta blocker with additional vasodilating property due to nitric oxide release. Aim: The current study aims to assess efficacy and safety of Nebivolol and compare with Atenolol. Materials and Methods: This was prospective, double blind, comparative controlled clinical study. Total 90 patients were enrolled into study as per selection criteria. Patients were randomized to receive Atenolol and Nebivolol with 45 patients in each group for 12 weeks. Results and Conclusion: The mean reduction diastolic blood pressure in Nebivolol and Atenolol group was 10.77 +/- 2.60 and 10.05 +/- 2.83 respectively. The number of patients with adverse effect events was higher in the Atenolol than in the Nebivolol group (36.84% of Atenolol Vs 12.82% of Nebivolol). Thus it can be concluded that, for the same antihypertensive effect, Nebivolol was better tolerated than Atenolol.

引用

页码：HC1 / HC4

页数：4

共 13 条

[1]

Lorenzo, G., Armando, M., Different effects of Antihypertensive drugs on conduct artery endothelial function (2003) Hypertension, 41, p. 1281

[2]

Ko, D.T., Patricia, R., B blocker Therapy and symptoms of Depression fatigue and sexual dysfunction (2002) JAMA, 288, pp. 351-357

[3]

McNeely, W., Goa, K.L., Nebivolol in the Management of Essential Hypertension (1999) Drugs, 57 (4), pp. 633-651

[4]

Kamp, O., Metra, M., Bugatti, S., Bettari, L., Cas, A.D., Petrini, N., Nebivolol Haemodynamic Effects and Clinical Significance of Combined b-Blockade and Nitric Oxide Release (2010) Drugs, 70 (1), pp. 41-56

[5]

Bortel, V., Breed, J.G.S., Kragten, J.A.J., Nebivolol in Hypertension: A Double- Blind placebo controlled multicenter study Assessing its antihypertensive Efficacy and impact- on quality of life (1993) J Cardiovascular Pharmacology, 21, pp. 856-862

[6]

Freestone, S., Silas, J.H., Ramsay, L.E., Sample size for short-term trials of antihypertensive drugs (1982) Br J Clin Pharmacol, 14 (2), pp. 265-268

[7]

van Nueten, L., Taylor, F.R., Robertson, J., Nebivolol Vs Atenolol and placebo in essential Hypertension: A double - Blind randomised trial (1998) J Hum. Hypertens, 12, pp. 135-140

[8]

Grassi, G., Trevano, F.Q., Facchini, K., Efficacy and tolerability profile of Nebivolol Vs atenolol in mild to moderate essential hypertension: Result of a double blind randomized multi center trial (2003) Blood Press Suppl, 2, pp. 35-40

[9]

Kamp, O., Sie'swerda, G.T., Cees, A., Comparison of effects on systolic and diastolic left ventricular function of Nebivolol versus Atenolol in patients with Uncomplicated Essential Hypertension (2003) Am. J. Cardiol, 92, pp. 344-348

[10]

Fogari, R., Zoppi, A., Lazzari, P., Mugellini, A., Comparative effects of Nebivolol and Atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes (1997) J Hum. Hyper Tens, 11, pp. 753-757

← 1 2 →